Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PYGB | P11216 | 1/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21059535 | 1.00 | GBA1 (0.49) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL31001202 | 1.00 | GBA1 (0.49) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL13281076 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL20897004 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL13281078 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL23906986 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL3832277 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL10786697 | 0.94 | GBA1 (0.59) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL23787746 | 0.94 | GBA1 (0.59) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| Hexane SCHEMBL28784867 | 0.94 | GBA1 (0.59) | GBA1KDM4ELMNACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023200882-A1 | COMPOSITIONS AND METHODS FOR TREATING POST ACUTE SEQUELAE OF SARS-COV-2 INFECTION (LONG COVID) | Vitro Biopharma, Inc. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20220389377-A1 | TREATMENT OF MEDICAL CONDITIONS BY STEM CELL TRANSPLANTS AND STEM CELL ACTIVATION | AE CAPITAL LIMITED (VG) | 2022-12-08 | — | — | US | disclosed |
| WO-2022224230-A1 | TREATMENT OF MEDICAL CONDITIONS BY STEM CELL TRANSPLANTS AND STEM CELL ACTIVATION | Vitro Biopharma, Inc. (US) | 2022-10-27 | — | — | WO | disclosed |